


EXPRESS MAIL NO. EV 346 792 763 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In the Application of: Haim AVIV et al.
Application No.: 10/644,687
Filing Date: August 19, 2003

For: HIGH ENANTIOMERIC PURITY
DEXANABINOL FOR PHARMACEUTICAL
COMPOSITIONS

Confirmation No. 6729
Group Art Unit: 1626
Examiner: Taofiq A. Solola
Attorney Docket No.:
87754-7500

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450


Sir:

Pursuant to applicants' duty of disclosure under 37 C.F.R. 1.56, enclosed are copies of eleven (11) further references for the Examiner's review and consideration. These references are listed on the enclosed Form PTO-1449. It is respectfully requested that these references be made of record in this application by the Examiner's completion and return of the PTO Form 1449.

The fee which is believed to be due for this submission is \$180. Please charge the required fee to Winston & Strawn LLP Deposit Account No. 50-1814.

Date: 3/9/05


Respectfully submitted,



Allan A. Fanucci 30,256
Reg. No.

WINSTON & STRAWN
Customer Number 28765
(212) 294-3311

03/16/2005 EABUBAK1 00000001 501814 10644687
01 FC:1806 180.00 DA



		ATTY. DOCKET NO.:	APPLICATION NO.:
		87754-7500	
APPLICANT:			10/644/687
Haim AVIV et al.			
FILING DATE:		GROUP:	
	August 19, 2003		1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						

FOREIGN PATENT DOCUMENTS

cont....

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AC							
	AD							

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

AE	Mechoulam R. and Hanuš L., "A Historical Overview Of Chemical Research On Cannabinoids", Chem. Phys. Lipids, Vol. 108, pp. 1-13 (2000).
AF	Mechoulam R. et al., "Synthesis Of The Individual, Pharmacologically Distinct, Enantiomers Of A Tetrahydrocannabinol Derivative", Tetrahedron Asymmetry, Vol. 1, No. 5, pp. 315-318, (1990).
AG	Ottani A. et al., "HU-210: A Potent Tool For Investigations Of The Cannabinoid System", CNS Drug Reviews, Vol. 7, No. 2, pp. 131-145, (2001).
AH	Levin S. et al. "Resolution Of Chiral Cannabinoids On Amylose Tris(3, 5-dimethylphenylcarbamate) Chiral Stationary Phase: Effects Of Structural Features And Mobile Phase Additives", Journal of Chromatography A., Vol. 654, pp.53-64, (1993).
AI	Pop E. et al, "Derivatives Of Dexanabinol I. Water-Soluble Salts Of Glycinate Esters", Pharmaceutical Research, Vol. 13, pp. 62-69, (1996).
AJ	Pop E. et al., "Derivatives Of Dexanabinol II. Salts Of Amino Acid Esters Containing Tertiary And Quaternary Heterocyclic Nitrogen With Increased Water-Solubility", Pharmaceutical Research, Vol. 13, pp469-475, (1996).
AK	Pop E. et al. "In Vitro And In Vivo Study Of Water-Soluble Prodrugs Of Dexanabinol", Pharmaceutical Research Sciences, Vol. 88, pp. 1156-1160, (1999)
AL	Pop E. et al, "Water-Soluble Combinations Of Dexanabinol: Prodrugs And Analogs", Pharmazie, Vol. 55, pp 167-171, (2000)
AM	Thomas B.F. et al., "Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency ¹ ", Journal Pharmacology and Experimental Therapeutics, Vol.. 255, pp. 624-630, (1990).

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AN	Brewster M. E. et al, "Clinical Pharmacokinetics Of Escalating i.v. Doses Of Dexanabinol (HU-211), A Neuroprotectant Agent, In Normal Volunteers", International Journal Of Clinical Pharmacology and Therapeutics, Vol. 35, pp.: 361-365, (1997)
	AO	Knoller N. et al, "Dexanabinol (HU-211) In The Treatment Of Severe Closed Head Injury: A Randomized, Placebo-Controlled, Phase II Clinical Trial" Crit. Care Med., Vol 30, pp. 548-554, (2002)
	AP	
	AQ	
	AR	
	AS	
EXAMINER		DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.